Early rhythm control for atrial fibrillation with tricuspid valve leakage
Part of Heart & circulation clinical trials.
This trial tests whether treating atrial fibrillation (an irregular heartbeat) early helps patients who also have tricuspid regurgitation (leakage in a heart valve). Researchers want to see if controlling the heart rhythm early can improve outcomes for people with both conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with atrial fibrillation (irregular heartbeat) and tricuspid regurgitation (heart valve leakage) at the same time or around the same time
- You have not had heart valve surgery in the past
- You do not have congenital heart disease (a heart condition you were born with)
- You do not have primary pulmonary hypertension (severe high blood pressure in the lungs)
- If you have a pacemaker or defibrillator (CIED), it was implanted after your tricuspid regurgitation was diagnosed
- Your tricuspid regurgitation was diagnosed before or at the same time you started treatment for your irregular heartbeat
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether starting treatment early to control your heart's rhythm can help people with a heart device who have short bursts of a fast heartbeat (called atrial high rate episodes) but haven't yet been diagnosed with atrial fibrillation on a standard EKG or Holter monitor.
This study looks at how atrial fibrillation (a common heart rhythm problem) affects the tricuspid valve—one of your heart's four valves. Researchers will use special ultrasound imaging to understand these changes and help improve future treatment.
This study tests whether a catheter ablation procedure (a way to fix abnormal heart rhythms) can help people who have both constant atrial fibrillation and severe mitral regurgitation (a leaky heart valve). It is for people whose heart valve leak is caused by the rhythm problem, not by valve damage.
This trial tests a new, less-invasive device called 'Pivot Extend' for people with a severe leaky tricuspid valve (tricuspid regurgitation) who still have symptoms despite taking medicines. The goal is to see if the device can safely help reduce the leak and improve symptoms.
This trial uses a special catheter to measure blood flow in patients with severe tricuspid regurgitation who are already scheduled for a valve repair or replacement. The goal is to see if this measurement helps doctors better predict who will benefit from the procedure.
This study tests a new catheter-based device to repair a leaky tricuspid heart valve (tricuspid regurgitation) in people who still have symptoms like shortness of breath or swelling despite taking heart medications. The goal is to see if the procedure is safe and can help reduce the leak.
Hear when a new Atrial Fibrillation (AF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.